NEWTON, Mass.--(BUSINESS WIRE)--PGxHealth™, a division of Clinical Data (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that its FAMILION® test for Long QT Syndrome (LQTS) has met the Blue Cross and Blue Shield Association Technology Evaluation Center’s (TEC) criteria for establishing the diagnosis of LQTS in certain individuals.
